DavidRSpigelMD

Clinical Trials

• Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer Start of enrollment: 2004 Apr 01

  Completed

  Phase 1, Phase 2

• Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Jul 01

  Completed

  Phase 2

• Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2005 May 01

  Completed

  Phase 2

• Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer Start of enrollment: 2004 Apr 01

  Completed

  Phase 2

• Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer Start of enrollment: 2005 Jul 01

  Completed

  Phase 2

• Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer Start of enrollment: 2006 Jan 01

  Completed

  Phase 2

• Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer Start of enrollment: 2006 Feb 01

  Completed

  Phase 2

• Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2006 Feb 01

  Completed

  Phase 2

• Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2006 Mar 01

  Completed

  Phase 2

• 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer Start of enrollment: 2006 Mar 01

  Completed

  Phase 2

• Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer Start of enrollment: 2006 Mar 01

  Completed

  Phase 2

• A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel Start of enrollment: 2006 Mar 01

  Terminated

  Phase 1

• A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01

  Completed

  Phase 1, Phase 2

• Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer Start of enrollment: 2006 Nov 01

  Terminated

  Phase 2

• First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC Start of enrollment: 2007 Mar 01

  Completed

  Phase 2

• Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) Start of enrollment: 2008 Feb 01

  Completed

  Phase 2

• Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib Start of enrollment: 2008 Mar 01

  Completed

  Phase 2

• Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors Start of enrollment: 2004 Jul 01

  Completed

  Phase 1

• Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC Start of enrollment: 2007 Dec 01

  Completed

  Phase 2

• Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer Start of enrollment: 2009 Feb 01

  Unknown status

  Phase 3

• Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer Start of enrollment: 2008 Sep 01

  Completed

  Phase 2

• PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors Start of enrollment: 2008 Oct 01

  Completed

  Phase 1

• Trial of Poor Performance Status Patients (ToPPS) Start of enrollment: 2009 Jun 01

  Completed

  Phase 2

• Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer Start of enrollment: 2009 Jun 01

  Completed

  Phase 2

• A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer Start of enrollment: 2009 Jul 01

  Completed

  Phase 2

• Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer Start of enrollment: 2010 Jan 01

  Completed

  Phase 2

• Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC Start of enrollment: 2010 Jun 01

  Completed

  Phase 2

• A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2009 Dec 01

  Completed

  Phase 2

• A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer Start of enrollment: 2010 Nov 01

  Terminated

  Phase 1, Phase 2

• Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11

  Terminated

  Phase 3

• Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib Start of enrollment: 2014 Mar 01

  Completed

  Phase 2

• Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer Start of enrollment: 2012 Oct 01

  Completed

• A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01

  Completed

  Phase 1, Phase 2

• Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Start of enrollment: 2013 Sep 09

  Terminated

  Phase 1

• LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28

  Completed

  Phase 3

• Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer Start of enrollment: 2013 Jul 01

  Completed

  Phase 2

• Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01

  Completed

  Phase 2

• A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy Start of enrollment: 2012 Jan 07

  Terminated

  Phase 1, Phase 2

• A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01

  Completed

  Phase 2

• Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01

  Completed

  Phase 2

• A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09

  Completed

  Phase 3

• A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer Start of enrollment: 2014 Mar 01

  Terminated

  Phase 2

• Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer Start of enrollment: 2014 Mar 01

  Terminated

  Phase 2

• A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations Start of enrollment: 2014 Apr 01

  Terminated

  Phase 2

• Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 16

  Terminated

  Phase 2

• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03

  Active, not recruiting

  Phase 3

• Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05

  Terminated

  Phase 1, Phase 2

• Join now to see all